☰

Namita L. Tundia, Ph.D. - Publications

Affiliations: 
2013 Pharmaceutical Sciences/Biopharmaceuticals University of Cincinnati, Cincinnati, OH 
Area:
Pharmacy, Public Health, Health Care Management
Tree Info Similar researchers PubMed Report error

34/58 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Sussman M, Tao C, Patel P, Tundia N, Clewell J, Menzin J. Cost-utility analyses of targeted immunomodulators in rheumatoid arthritis: systematic review. Journal of Medical Economics. 1. PMID 31971039 DOI: 10.1080/13696998.2020.1720219  0.313
2020 Bergman M, Zhou L, Patel P, Sawant R, Clewell J, Tundia N. Thu0546 Healthcare Costs Of Not Achieving Remission In Patients With Rheumatoid Arthritis Annals of the Rheumatic Diseases. 79: 513-513. DOI: 10.1136/Annrheumdis-2020-Eular.955  0.407
2020 Bensimon A, Yang M, Orvis E, Clewell J, Tundia N. Ab1148 Economic Benefit From Improvements In Health-Related Quality Of Life With Upadacitinib And Comparisons With Tofacitinib And Methotrexate In Patients With Moderately To Severely Active Rheumatoid Arthritis Annals of the Rheumatic Diseases. 79: 1864-1865. DOI: 10.1136/Annrheumdis-2020-Eular.500  0.395
2020 Kremer JM, Winkler A, Anatale-Tardiff L, Mclean R, Shan Y, Moore P, Tundia N, Suboticki J, Tesser J. Fri0100 Comparison Of Patients (Pts) With Rheumatoid Arthritis (Ra) Among Disease Activity Categories After 6 Months Of Treatment With A Tumour Necrosis Factor Inhibitor (Tnfi): Results From The Corrona® Ra Registry Annals of the Rheumatic Diseases. 79: 629-629. DOI: 10.1136/Annrheumdis-2020-Eular.1698  0.306
2019 Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff M. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. Arthritis Research & Therapy. 21: 272. PMID 31815649 DOI: 10.1186/S13075-019-2037-1  0.35
2019 Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, Song Y, Pope J. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. Arthritis Research & Therapy. 21: 263. PMID 31791386 DOI: 10.1186/S13075-019-2059-8  0.357
2019 Strand V, Shah R, Atzinger C, Zhou J, Clewell J, Ganguli A, Tundia N. Economic burden of fatigue or morning stiffness among patients with rheumatoid arthritis: a retrospective analysis from real world data. Current Medical Research and Opinion. 1. PMID 31433680 DOI: 10.1080/03007995.2019.1658974  0.364
2019 Strand V, Tundia N, Radominski S, Friedman A, Dunlap K, Goldschmidt D, Bergman M. Thu0192 Upadacitinib Monotherapy Improves Patient-Reported Outcomes In Methotrexate-Naïve Patients With Moderately To Severely Active Rheumatoid Arthritis: Results From Select-Early Annals of the Rheumatic Diseases. 78: 372-373. DOI: 10.1136/Annrheumdis-2019-Eular.978  0.355
2019 Strand V, Bergman M, Tundia N, Ostor A, Durez P, Song I, Enejosa JJ, Schlacher C, Song Y, Fleischmann R. Fri0137 Upadacitinib Improves Patient-Reported Outcomes In Patients With Rheumatoid Arthritis And Inadequate Response To Methotrexate: Results From Select-Compare Annals of the Rheumatic Diseases. 78: 738-739. DOI: 10.1136/Annrheumdis-2019-Eular.287  0.353
2019 Harrold L, Litman HJ, O’brien J, Feng H, Schlacher C, Tundia N. FRI0152 METHOTREXATE TREATMENT PATTERNS IN ADVANCED THERAPY–NAïVE PATIENTS WITH RHEUMATOID ARTHRITIS: CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS IN THE CORRONA REGISTRY Annals of the Rheumatic Diseases. DOI: 10.1136/Annrheumdis-2019-Eular.1009  0.305
2018 Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis. Journal of Managed Care & Specialty Pharmacy. 24: 344-352. PMID 29578852 DOI: 10.18553/Jmcp.2018.24.4.344  0.349
2018 Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, Song Y, Pope J. SAT0255 Patient reported outcomes of upadacitinib: results from biologic inadequate responders (SELECT BEYOND PHASE III TRIAL) Annals of the Rheumatic Diseases. 77: 990-990. DOI: 10.1136/Annrheumdis-2018-Eular.1254  0.359
2016 Michetti P, Weinman J, Mrowietz U, Smolen J, Peyrin-Biroulet L, Louis E, Schremmer D, Tundia N, Nurwakagari P, Selenko-Gebauer N. Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study. Advances in Therapy. PMID 27854054 DOI: 10.1007/S12325-016-0441-3  0.33
2016 Guandalini S, Tundia N, Thakkar R, Macaulay D, Essenmacher K, Fuldeore M. Direct Costs in Patients with Celiac Disease in the USA: A Retrospective Claims Analysis. Digestive Diseases and Sciences. PMID 27417565 DOI: 10.1007/S10620-016-4219-X  0.319
2016 Tundia N, Gustavo Kotze P, Rojas Serrano J, Mendes de Abreu M, Skup M, Macaulay D, Signorovitch J, Chaves L, Chao J, Bao Y. Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia and Mexico. Journal of Medical Economics. 1-49. PMID 27376404 DOI: 10.1080/13696998.2016.1209508  0.312
2015 Guandalini S, Tundia N, Thakkar R, Arunajadai S, Macaulay D, Essenmacher K, Fuldeore M. Sa1283 Prevalence of Comorbidities in Patients With Celiac Disease Gastroenterology. 148. DOI: 10.1016/S0016-5085(15)30923-9  0.302
2015 Guandalini S, Tundia N, Thakkar R, Arunajadai S, Macaulay D, Essenmacher K, Fuldeore M. 2 Direct Costs in Patients With Celiac Disease - A Retrospective Claims Analysis Gastroenterology. 148. DOI: 10.1016/S0016-5085(15)30002-0  0.342
2015 Tundia N, Hass S, Fuldeore M, Wang LL, Cavanaugh T, Boone J, Heaton P. Validation and u.s. Population norms of health-related productivity questionnaire Value in Health. 18. DOI: 10.1016/J.Jval.2015.03.148  0.484
2014 Liu Y, Tundia N, Skup M, Ayyagari R, Du E, Chao J, Mulani P, Bao Y. AB0414 Claims Database Analysis of Adherence to Adalimumab Therapy and Health Care Costs for Patients with Rheumatoid Arthritis Annals of the Rheumatic Diseases. 73: 944.1-944. DOI: 10.1136/Annrheumdis-2014-Eular.2287  0.416
2014 Michetti P, Weinman J, Mrowietz U, Smolen J, Schremmer D, Tundia N, Gillas F, Selenko-Gebauer N. FRI0198 Multi-Country, Cross-Sectional Study to Determine Patient-Specific and General Beliefs towards Medication and their Treatment Adherence to Selected Systemic Therapies in 6 Chronic Immune-Mediated Inflammatory Diseases (ALIGN) Annals of the Rheumatic Diseases. 73: 454-454. DOI: 10.1136/Annrheumdis-2014-Eular.2030  0.336
2014 Tundia N, Skup M, Oye B, Okalibe X, Chao J, Bao Y, Dick A. Cost of complications for patients with non-infectious non-anterior uveitis Acta Ophthalmologica. 92: 0-0. DOI: 10.1111/J.1755-3768.2014.F076.X  0.356
2014 Thorne J, Tundia N, Skup M, Macaulay D, Revol C, Chao J, Bao Y, Dick A. Healthcare resource use and costs in persistent non-anterior non-infectious uveitis Acta Ophthalmologica. 92: 0-0. DOI: 10.1111/J.1755-3768.2014.3441.X  0.347
2013 Heaton PC, Tundia NL, Luder HR. U.S. emergency departments visits resulting from poor medication adherence: 2005-07. Journal of the American Pharmacists Association : Japha. 53: 513-9. PMID 24030129 DOI: 10.1331/Japha.2013.12213  0.549
2013 Heaton P, Tundia NL, Schmidt N, Wigle PR, Kelton CM. Authors' response. Journal of Pediatric Gastroenterology and Nutrition. 56: e12. PMID 23201700 DOI: 10.1097/MPG.0b013e31827e20c7  0.385
2013 Tundia NL, Kelton CM, Cavanaugh TM, Guo JJ, Hanseman DJ, Heaton PC. The effect of electronic medical record system sophistication on preventive healthcare for women. Journal of the American Medical Informatics Association : Jamia. 20: 268-76. PMID 23048007 DOI: 10.1136/Amiajnl-2012-001099  0.498
2013 Schifrien B, Yen E, Liu Y, Skup M, Tundia N, Ayyagari R, Yang H, Bao Y, Mulani P, Chao J. Association between Adherence to Adalimumab Therapy and Health Care Costs for Patients with Crohnʼs Disease: Claims Database Analysis American Journal of Gastroenterology. 108: S514-S515. DOI: 10.14309/00000434-201310001-01708  0.371
2012 Heaton PC, Tundia NL, Schmidt N, Wigle PR, Kelton CM. National burden of pediatric hospitalizations for inflammatory bowel disease: results from the 2006 Kids' Inpatient Database. Journal of Pediatric Gastroenterology and Nutrition. 54: 477-85. PMID 22027564 DOI: 10.1097/Mpg.0B013E318239Bc79  0.543
2012 Desai VC, Kelton CM, Tundia NL, Heaton PC. PDB103 Predictors of Hospital Readmissions in Patients With Diabetes: Results From the 1999-2009 Medical Expenditure Panel Survey Value in Health. 15. DOI: 10.1016/J.Jval.2012.03.1024  0.336
2011 Tundia NL, Heaton PC, Kelton CM. The national burden of E-code-identified adverse drug events among hospitalized children using a national discharge database. Pharmacoepidemiology and Drug Safety. 20: 866-78. PMID 21574209 DOI: 10.1002/Pds.2150  0.542
2011 Tundia N, Heaton P, Cavanaugh T, Guo JJ, Hanseman D, Kelton CM. Pih39 The Effect Of Electronic-Medical-Record System Sophistication On Preventive Health Care For Women Value in Health. 14. DOI: 10.1016/J.Jval.2011.02.623  0.507
2011 Tundia N, Desai VC, Berry E, Heaton PC. Pdb47 National Impact Of Health Care Access On Health-Related Quality Of Life Of Patients With Diabetes In The United States Value in Health. 14. DOI: 10.1016/J.Jval.2011.02.555  0.556
2010 Tundia N, Heaton P, Kelton C. Pih1 The National Burden Of Pediatric Adverse Drug Events: A Case-Control Study Using The 2006 Kids' Inpatient Database Value in Health. 13. DOI: 10.1016/S1098-3015(10)72878-3  0.514
2010 Tundia N, Guo J, Wigle P, Heaton P. Pnd35 Antiepileptic Drug Utilization and Medicaid Reimbusement Trends From 1991 to 2008 Value in Health. 13. DOI: 10.1016/S1098-3015(10)72697-8  0.484
2010 Tundia N, Heaton P, Kelton C. Pgi11 Pediatric Hospitalizations For Inflammatory Bowel Disease: Results From 2006 Kids' Inpatient Database Value in Health. 13. DOI: 10.1016/S1098-3015(10)72330-5  0.516
Low-probability matches (unlikely to be authored by this person)
2016 Thorne JE, Skup M, Tundia N, Macaulay D, Revol C, Chao J, Joshi A, Dick AD. Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis. Acta Ophthalmologica. PMID 26932535 DOI: 10.1111/Aos.12987  0.298
2017 Strand V, Tundia N, Song I, Meerwein S, Lin J, Chen N, Friedman A. SAT0217 Early patient-reported outcomes and clinical outcomes with abt-494 in patients with active rheumatoid arthritis who are inadequate responders to methotrexate or tumor necrosis factor inhibitors: post-hoc analysis of phase 2 randomized controlled trials Annals of the Rheumatic Diseases. DOI: 10.1136/Annrheumdis-2017-Eular.1143  0.283
2018 Foley C, Tundia N, Simpson E, Teixeira HD, Litcher-Kelly L, Bodhani A. Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: The Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS). Current Medical Research and Opinion. 1. PMID 30561230 DOI: 10.1080/03007995.2018.1560222  0.278
2015 Rojas Serrano J, de Abreu MM, Tundia N, Skup M, Sorg R, Macaulay D, Bao Y, Chaves L, Chao J. Projected Economic Impact of Increased Use of Biologic Treatments For Rheumatoid Arthritis In Argentina, Colombia, And Mexico Over 10 Years. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 18: A806. PMID 26534297 DOI: 10.1016/J.Jval.2015.09.079  0.273
2012 Tundia NL, Heaton PC, Kelton CM, Hass S, Fuldeore M. PR3 Qualitative Assessment of Health-Related Productivity Instruments Value in Health. 15. DOI: 10.1016/J.Jval.2012.03.065  0.269
2015 Chao J, Skup M, Alexander E, Tundia N, Macaulay D, Wu E, Mulani P. Nomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names. Advances in Therapy. 32: 270-83. PMID 25772256 DOI: 10.1007/S12325-015-0193-5  0.266
2012 Tundia N, Bhor M, Duhig A, Hass S, Perry R, Milligan G. PMH58 Impact of Positive and Negative Symptoms and Cognitive Impairment on Health Outcomes and Healt Care Resource Utilization in European Patients with Schizophrenia Value in Health. 15: A92. DOI: 10.1016/J.Jval.2012.03.503  0.265
2014 DICK A, TUNDIA N, SKUP M, SORG R, ZHAO C, BAO Y, CHAO J. Risk of ocular complications in persistent non-infectious non-anterior uveitis Acta Ophthalmologica. 92: 0-0. DOI: 10.1111/J.1755-3768.2014.F078.X  0.262
2015 Kotze PG, Tundia N, Gumen A, Macaulay D, Chaves L, Bao Y. Economic Impact of Expanded Use of Biologic Therapy for Crohn's Disease In Latin American Countries. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 18: A867. PMID 26534640 DOI: 10.1016/J.Jval.2015.09.524  0.26
2020 Pope J, Sawant R, Tundia N, Du EX, Qi CZ, Song Y, Tang P, Betts KA. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis. Advances in Therapy. PMID 32297280 DOI: 10.1007/S12325-020-01303-3  0.256
2012 Tundia NL, Fuldeore M, Gruca D, Hass S, Bacher P, Bodhani A. PCN89 Cost Effectiveness of Treatment With New 6-Month Leuprorelin Acetate Formulation in Patients With Advanced Prostate Cancer Value in Health. 15. DOI: 10.1016/J.Jval.2012.08.2129  0.256
2015 Dick AD, Tundia N, Sorg R, Zhao C, Chao J, Joshi A, Skup M. Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Ophthalmology. PMID 26712559 DOI: 10.1016/J.Ophtha.2015.10.028  0.256
2022 Bergman M, Tundia N, Martin N, Suboticki JL, Patel J, Goldschmidt D, Song Y, Wright GC. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial. Arthritis Research & Therapy. 24: 155. PMID 35751108 DOI: 10.1186/s13075-022-02813-x  0.243
2020 Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff M. Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. Arthritis Research & Therapy. 22: 137. PMID 32517782 DOI: 10.1186/s13075-020-02238-4  0.236
2022 Bergman M, Tundia N, Martin N, Suboticki JL, Patel J, Goldschmidt D, Song Y, Wright GC. Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial. Arthritis Research & Therapy. 24: 248. PMID 36329507 DOI: 10.1186/s13075-022-02940-5  0.232
2021 Bergman M, Zhou L, Patel P, Sawant R, Clewell J, Tundia N. Healthcare Costs of Not Achieving Remission in Patients with Rheumatoid Arthritis in the United States: A Retrospective Cohort Study. Advances in Therapy. PMID 33837497 DOI: 10.1007/s12325-021-01730-w  0.221
2021 Strand V, Tundia N, Bergman M, Ostor A, Durez P, Song IH, Enejosa J, Schlacher C, Song Y, Fleischmann R. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. Rheumatology (Oxford, England). PMID 33590829 DOI: 10.1093/rheumatology/keab158  0.201
2021 Bergman M, Tundia N, Yang M, Orvis E, Clewell J, Bensimon A. Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis. Advances in Therapy. PMID 34636000 DOI: 10.1007/s12325-021-01930-4  0.197
2020 Strand V, Tundia N, Wells A, Buch MH, Radominski SC, Camp HS, Friedman A, Suboticki JL, Dunlap K, Goldschmidt D, Bergman M. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY. Rheumatology (Oxford, England). PMID 33313898 DOI: 10.1093/rheumatology/keaa770  0.192
2023 Harrold LR, Zueger P, Nowell WB, Blachley T, Schrader A, Lakin PR, Curtis D, Stradford L, Venkatachalam S, Tundia N, Patel PA. A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis. Rheumatology and Therapy. PMID 37728861 DOI: 10.1007/s40744-023-00594-6  0.18
2021 Pope J, Sawant R, Tundia N, Du EX, Qi CZ, Song Y, Tang P, Betts KA. Authors' Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis. Advances in Therapy. PMID 33742364 DOI: 10.1007/s12325-021-01642-9  0.118
2023 Song Y, Wang Y, Wong SL, Yang D, Sundar M, Tundia N. Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States. Multiple Sclerosis and Related Disorders. 79: 105052. PMID 37832254 DOI: 10.1016/j.msard.2023.105052  0.112
2022 Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, Kalincik T, Van Der Walt A, Yamout B, Lechner-Scott J, Soysal A, Kuhle J, Sanchez-Menoyo JL, Blanco Morgado Y, Spitaleri D, ... ... Tundia N, et al. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry. Multiple Sclerosis (Houndmills, Basingstoke, England). 13524585221137502. PMID 36433775 DOI: 10.1177/13524585221137502  0.102
2023 Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, Kalincik T, Der Walt AV, Yamout B, Lechner-Scott J, Soysal A, Kuhle J, Sanchez-Menoyo JL, Morgado YB, Spitaleri D, ... ... Tundia N, et al. A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry. Neurodegenerative Disease Management. PMID 37287269 DOI: 10.2217/nmt-2023-0005  0.095
Hide low-probability matches.